U.S. Consumer Durables Stock News

Earlier this month, The Hershey Company reaffirmed its 2026 guidance for net sales and earnings growth and expanded its Reese’s lineup with limited-time Marshmallow and Strawberry PB&J Cups, responding to strong consumer demand for nostalgic flavor mashups. At the same time, meaningful insider selling by Hershey Trust Company and other insiders has added a layer of investor caution around the otherwise upbeat product and guidance news. Next, we’ll examine how the insider selling alongside...

Citigroup (NYSE:C) reported its strongest quarterly results in a decade in Q1 2026, with net income up 42% year over year. The bank delivered record revenue in its markets segment, supported by double digit gains in both trading and investment banking. Wealth management revenue also showed significant growth, contributing to overall earnings strength. Citigroup reported substantial progress on its transformation plan, including asset divestitures and share repurchases. For investors...

Why Campbell's stock is drawing attention now Campbell's (CPB) is under the microscope after an extended slide, with the share price showing negative returns over the past year and past 3 months, and closing at $20.17 most recently. See our latest analysis for Campbell's. The recent 1 week share price return of 8.4% and 3 month share price return of 22.75% decline sit alongside a 1 year total shareholder return of 45.08% decline and a 3 year total shareholder return of 58.55% decline. This...

Wondering if AAR is still reasonably priced after a strong run, or if you might be arriving late to the story? This article walks through what the current share price could mean for you. At a last close of US$123.77, AAR has returns of 8.6% over 7 days, 21.5% over 30 days, 46.6% year to date, 128.3% over 1 year, 127.8% over 3 years and 211.1% over 5 years. This naturally raises questions about what is already reflected in the price. The recent moves sit against a backdrop of ongoing interest...

Nutanix (NTNX) has come under pressure after a series of analyst downgrades, including JPMorgan shifting its rating to Neutral. Investors are reassessing the stock in light of tougher macro expectations and increased competition. See our latest analysis for Nutanix. The share price has been volatile, with an 8.4% 1 day gain to US$37.30 following a series of sharp pullbacks, including a 29.1% 3 month share price decline and a 38.23% 1 year total shareholder return loss, even as the 3 year...

TransMedics Group recently reported strong 2025 operational results, including over 5,100 U.S. Organ Care System transplants, its first full year of positive cash flow, improved operating margins, and a fleet acquisition to bolster logistics for its National OCS Program. An interesting angle is that these operational milestones come alongside both insider stock sales of about US$2.4 million and earlier insider purchases, offering a mixed but informative window into management...

Viatris (NasdaqGS:VTRS) is presenting four Phase 3 ophthalmic clinical study abstracts at the 2026 ASCRS Annual Meeting. The data include new findings in presbyopia and visual disturbance treatments using phentolamine ophthalmic solutions. These late stage results may be important for Viatris' ophthalmology portfolio and potential future product approvals. For investors tracking NasdaqGS:VTRS at a share price of $13.83, this spotlight on Phase 3 ophthalmic data comes on top of a share price...

Littelfuse, a supplier of electrical protection and control components, has recently attracted attention as it expands into power semiconductors and electric vehicle charging infrastructure while contending with flat sales, declining earnings per share, and weaker returns on invested capital over the past two years. This mix of ambitious expansion into newer electrification markets and concerns about past investment effectiveness is drawing closer scrutiny of how Littelfuse balances growth...

In early April 2026, Alnylam Pharmaceuticals highlighted new clinical data for its ATTR-CM therapy vutrisiran at the American College of Cardiology meeting, while also marking free cash flow breakeven in 2025 and continued recognition for its RNAi-based cardiovascular portfolio. Investor interest was further underlined as a large-cap growth fund added Alnylam to its portfolio, aligning institutional conviction with improving financial footing and reinforcing attention on the company’s...

Earlier this month, Constellation Energy Corporation outlined plans for US$3.90 billion in 2026 capital spending and expanded its share repurchase authorization to US$5.00 billion to support rising US demand for clean electricity. This combination of heavier investment in carbon-free capacity and a larger buyback program highlights how Constellation is balancing growth with returning capital to shareholders. Now we’ll assess how Constellation’s larger share repurchase authorization could...

If you are wondering whether Intuit's current share price reflects its true worth, you are not alone. A closer look at the numbers can help you frame that question more clearly. After reaching a last close of US$369.44, the stock has seen 7 day, 30 day, year to date and 1 year returns of 9.9% decline, 16.0% decline, 41.3% decline and 37.3% decline respectively. This may be reshaping how the market views both its potential and its risks. Recent headlines around Intuit have focused on ongoing...

NextDecade Corporation recently announced it will host a conference call and webcast on May 1, 2026, to review its first-quarter 2026 developments, accompanied by a press release and presentation on its website. This update comes as the company’s liquefied natural gas and carbon capture ambitions intersect with weaker sector sentiment following a US-Iran ceasefire that pressured natural gas prices. Against this backdrop, we will examine how shifting energy-sector sentiment tied to the...

To move beyond the headline moves in Syndax Pharmaceuticals and really understand whether the current share price offers value, you need to look at how the stock compares on a few different valuation measures. The shares last closed at US$24.25, with returns of 3.2% over 30 days, 13.8% year to date and 115.7% over the past year. This naturally raises questions about whether expectations or risk perceptions have shifted. Recent coverage has focused on Syndax Pharmaceuticals as part of the...

Avnet stock performance snapshot Avnet (AVT) has drawn fresh attention after a solid run, with the share price at $73.48 and total returns of 23% over the past month and 47% over the past 3 months. See our latest analysis for Avnet. The recent 9.6% 1 day share price return and 17.7% 7 day share price return sit on top of a much stronger backdrop, with a 1 year total shareholder return of 63.0% and 5 year total shareholder return of 89.9% pointing to sustained momentum. If this kind of move...

Earlier today, data center operator IREN Ltd extended its winning streak as part of a broader tech rally, with trading activity supported by bullish technical signals after the stock moved above its 50-day moving average. An important angle for investors is the sharp rise in short interest, which increases the risk of abrupt price moves if bearish positions are forced to unwind. Next, we'll explore how this technical momentum and heightened short interest interact with IREN's existing...

If you are wondering whether Autoliv's current share price reflects its true worth, you are not alone. This article breaks down what the market might be pricing in and what it could be missing. Autoliv's share price recently closed at US$110.38, with returns of 4.9% over the past week, 7.3% over the past month, a 9.6% decline year to date, and 37.3% over the past year. Recent coverage around Autoliv has focused on its position in the auto components space and how investors are assessing its...

CTS (NYSE:CTS) is reporting stagnant sales and earnings as end markets soften and competition increases. Profitability and returns on capital are under pressure compared with industry peers. These operational headwinds raise questions about how the company will protect margins and allocate capital. For investors tracking NYSE:CTS, the current share price of $55.57 comes after strong stock performance, with the shares up 14.8% over the past week and 21.4% over the past month. The stock is...

Context for Starbucks Stock Right Now With no single headline event driving Starbucks (SBUX) today, investors are instead looking at the current share price of US$97.48 and recent return patterns to understand how the stock is behaving. See our latest analysis for Starbucks. Recent trading has been mixed, with a 0.91% 1 day share price return and a 2.38% 7 day share price return sitting alongside a 1.68% 30 day share price decline. The 1 year total shareholder return of 19.66% contrasts with...

Bread Financial Holdings (BFH) is back in focus after rising optimism around its upcoming earnings report, recent earnings beats, a new passive stake from Dimensional Fund Advisors, and fresh media attention on its branded credit card niche. See our latest analysis for Bread Financial Holdings. At a share price of US$80.19, Bread Financial has seen strong momentum recently, with a 30 day share price return of 12.11% and a 1 year total shareholder return of 80.89%, while the 3 year total...

If you are wondering whether Kenvue's current share price offers value or just more volatility, looking closely at what you are paying for each dollar of the business becomes crucial. The stock recently closed at US$17.26, with returns of a 0.2% decline over 7 days, a 1.3% decline over 30 days, a 0.3% decline year to date, and a 20.7% decline over the past year, which may change how investors think about both its potential and its risks. Recent headlines around Kenvue have focused on how it...

Several major brokerages recently lifted their views on Celanese (CE), citing growing optimism around earnings and potential growth across core end markets. This has brought fresh attention to the stock’s recent performance. See our latest analysis for Celanese. The recent broker upgrades have come alongside strong momentum in Celanese’s share price, with a 48.69% 3 month share price return, a 61.81% year to date share price return, and a 74.50% 1 year total shareholder return, contrasting...

GitLab (GTLB) is back in focus after a Guggenheim downgrade highlighted artificial intelligence as a potential disruptor to its core SaaS model. This has underscored investor questions around pricing, competition and new product traction. See our latest analysis for GitLab. Those AI concerns have landed on a stock that was already under pressure, with a 90 day share price return of -44.61% and a 1 year total shareholder return decline of 54.11%, pointing to fading momentum. If you are...

Amprius Technologies (AMPX) is back in focus after fresh commentary at the 38th Annual Roth Conference, where management outlined a move toward outsourced manufacturing, progress on silicon anode batteries, and targets for higher margins and revenue. See our latest analysis for Amprius Technologies. The recent commentary on outsourced manufacturing and silicon anode progress comes after a strong run, with the 90 day share price return of 90.18% and a very large 1 year total shareholder return...

Stryker (NYSE:SYK) has agreed to acquire Amplitude Vascular Systems, adding next generation intravascular lithotripsy technology to its portfolio. The deal expands Stryker's presence in vascular care and peripheral arterial disease treatments. The acquisition introduces Stryker to the intravascular lithotripsy market, an area with ongoing product development and unmet clinical needs. Stryker enters this transaction with its shares at $347.24 and a mixed recent return profile, including 4.5%...